OpenMed-NER-OncologyDetect-MultiMed-335M

モデル紹介

This model is a **state-of-the-art** fine-tuned transformer engineered to deliver **enterprise-grade accuracy** for cancer genetics - cancer-related genetic entities. This specialized model excels at identifying and extracting biomedical entities from clinical texts, research papers, and healthcare documents, enabling applications such as **drug interaction detection**, **medication extraction from patient records**, **adverse event monitoring**, **literature mining for drug discovery**, and **biomedical knowledge graph construction** with **production-ready reliability** for clinical and research applications. The BioNLP 2013 CG (Cancer Genetics) corpus is a specialized dataset focusing on cancer genetics entities and gene regulation in oncology research. This corpus contains annotations for genes, proteins, and molecular processes specifically related to cancer biology and tumor genetics. Developed for the BioNLP Shared Task 2013, it supports the development of text mining systems for cancer research, oncological studies, and precision medicine applications. The dataset is particularly valuable for identifying cancer-related biomarkers, tumor suppressor genes, oncogenes, and therapeutic targets mentioned in cancer research literature. It serves as a benchmark for evaluating NER systems used in cancer genomics, personalized medicine, and oncology informatics. *Figure: OpenMed (Open-Source) vs. Latest SOTA (Closed-Source) performance comparison across biomedical NER datasets.*

主な特徴

特点摘要待依据来源补齐，不凭模型名称推断能力。

制約と注意点

具体的な制約を判断する出典が不足しています。実際の性能、遅延、データ方針、ライセンス、提供期間を確認してください。

出典別料金と費用分析

料金はチャネル・地域・設定によって異なります。各チャネルの料金は個別に表示し、提供元の統一公式料金とは見なしません。

公開評価と実行設定

暂无已采集的可核验公开评分。模型未上榜不代表能力较低。

よくある質問

出典と追跡記録

许可证：apache-2.0。模型介绍与第三方评测均以原来源的具体版本和方法为准。